Advanced search
Start date
Betweenand
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

OPENING THE PANDORA’S BOX OF NANOMEDICINE: THERE IS INDEED‘PLENTY OF ROOM AT THE BOTTOM’

Full text
Author(s):
Alexsandra Conceição Apolinário [1] ; Giovanna Cassone Salata [2] ; Arthur F. R. Bianco [3] ; Claudio Fukumori [4] ; Luciana Biagini Lopes [5]
Total Authors: 5
Affiliation:
[1] Universidade de São Paulo. Instituto de Ciências Biomédicas. Departamento de Farmacologia - Brasil
[2] Universidade de São Paulo. Instituto de Ciências Biomédicas. Departamento de Farmacologia - Brasil
[3] Universidade de São Paulo. Instituto de Ciências Biomédicas. Departamento de Farmacologia - Brasil
[4] Universidade de São Paulo. Instituto de Ciências Biomédicas. Departamento de Farmacologia - Brasil
[5] Universidade de São Paulo. Instituto de Ciências Biomédicas. Departamento de Farmacologia - Brasil
Total Affiliations: 5
Document type: Journal article
Source: Química Nova; v. 43, n. 2, p. 212-225, 2020-05-18.
Abstract

Limitations of conventional treatment and dosage forms prompted the investigation of novel approaches that combine efficacy, selectivity and fewer adverse effects. These are the main promises of nanomedicine, generally defined as the application of nanotechnology to the biomedical field. Despite the considerable advances over the years and the large number of publications resulting from the growth of nanomedicine, there are still many hurdles and unknown factors limiting its successful translation from promise to reality. These factors range from the lack of standardization in the terminology and regulations, to the lack of understanding of interactions between nanocarriers and the biological system, and their influence on drug pharmacodynamics. In this manuscript, we aim at presenting and discussing concepts and terminologies used in the nanomedicine field and examining the main types of nanocarriers and their effects to modulate biological barriers and aid drug transport, bioavailability and targeting. (AU)

FAPESP's process: 18/13877-1 - Nanocarriers for localized treatment and chemoprevention of breast tumors
Grantee:Luciana Biagini Lopes
Support type: Research Grants - Young Investigators Grants - Phase 2
FAPESP's process: 14/50928-2 - INCT 2014: Pharmaceutical Nanotechnology: a transdisciplinary approach
Grantee:Maria Vitória Lopes Badra Bentley
Support type: Research Projects - Thematic Grants
FAPESP's process: 17/23213-0 - Biorresponsive systems for sustained drug release and breast cancer chemoprevention
Grantee:Giovanna Cassone Salata
Support type: Scholarships in Brazil - Master
FAPESP's process: 18/14375-0 - Nanotechnology-based topical delivery systems for breast cancer chemoprevention
Grantee:Alexsandra Conceição Apolinário
Support type: Scholarships in Brazil - Post-Doctorate